X4 Pharmaceuticals, Inc. (XFOR)

NASDAQ: XFOR · USD

$3.32

+0.07 (+2.1%)· Recorded snapshot

Market cap	329.2M
Revenue (ttm)	15.8M
Net income (ttm)	-90.1M
EPS (ttm)	-$0.89
Shares out	99.1M
Volume	435,718
Beta	0.46

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 15.8M
Net income (ttm): -90.1M
EPS (ttm): -$0.89
Market cap: 329.2M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Aanhouden

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-113.1

P25 n/aP50 n/aP75 n/a

ROIC-326.5

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All XFOR indicators

Market & fundamental data

Available fields

202

Groups with data

Currency

USD

Showing 202 of 202 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001501697
Company name	X4 Pharmaceuticals, Inc.
Country	United States
Country code	US
CUSIP number	98420X202
Earnings date	2026-11-09
Earnings time	bmo
Employees	45
Employees change	-98
Employees growth	-68.53%
Enterprise value	$198.4M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2014
In index	RUSSELL2000
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US98420X2027
Last 10-K release date	2026-03-17
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split date	2025-04-28
Last stock split type	Reverse
Market cap	$329.2M
Market cap category	Small-Cap
Next earnings date	2026-11-09
Options	Yes
Price	$3.32
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	XFOR
U.S. state	Massachusetts
Website	https://www.x4pharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-26.71%
EV/Sales	12.4x
FCF / EV yield	-42.63%
FCF yield	-25.59%
Forward EV/Sales	20.51x
Forward P/S	34.15x
P/B ratio	2.01x
P/S ratio	20.65x
Price / tangible book value	2.62x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	81.51%
Operating margin	-509.06%
Pretax margin	-568.98%
Profit per employee	$-2M
Revenue per employee	$352,156
ROA	-28.15%
ROA (5Y)	-41.4%
ROCE	-34.52%
ROE	-113.08%
ROE (5Y)	-120.96%
ROIC	-326.48%
SBC / revenue	53.83%
Tax / revenue	-0.18%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	1
EPS growth years	4
Gross profit growth	-52.52%
Gross profit growth (Q)	336.49%
Net income growth quarters	1
Net income growth years	0
Revenue growth	-51.65%
Revenue growth (Q)	346.33%
Revenue growth (QoQ)	225.18%
Revenue growth quarters	1
Revenue growth years	1

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Depreciation and amortization	$1.7M
EBIT	$-80.7M
EBITDA	$-79M
EPS	$-0.89
FCF per share	$-0.84
Financing cash flow	$233.1M
Free cash flow	$-83.7M
Free cash flow minus SBC	$-92.3M
Gross profit	$12.9M
Income taxes	$-28,000
Investing cash flow	$6.4M
Net cash flow	$155.7M
Net income	$-90.1M
Operating cash flow minus SBC	$-92.3M
Operating income	$-80.7M
Revenue	$15.8M
Stock-based compensation	$8.5M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-1.99
Book value per share	$1.62
Debt / equity	0.5
Goodwill	$17.4M
Interest coverage	-9.23
Long-term assets	$34.2M
Long-term liabilities	$78.2M
Net cash (debt)	$130.7M
Net cash / market cap	39.96%
Net debt / equity	-0.84
Piotroski F-Score	2
Property, plant and equipment	$765,000
Shareholders' equity	$155.5M
Tangible book value	$125M
Tangible book value per share	$1.30
Total assets	$253.1M
Total cash	$208M
Total debt	$77.2M
Total liabilities	$97.6M
WACC	7.2%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.09
Current assets	$218.9M
Current liabilities	$19.4M
Current ratio	11.3
Inventory turnover	0.68
Net working capital	$-8M
Quick ratio	10.84
Working capital	$199.5M
Working capital turnover	0.13

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-1,374.07%
Dividend yield	0%
Shareholder yield	-1,374.07%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$3.85
1D price change	2.15%
1M price change	10.3%
1M total return	10.3%
1W price change	10.3%
1W total return	10.3%
1Y price change	-11.23%
1Y return CAGR	-11.24%
1Y total return	-11.23%
20-day SMA	$2.90
200-day SMA	$3.81
3M price change	-15.74%
3M total return	-15.74%
3Y price change	-84.37%
3Y return CAGR	-46.13%
3Y total return	-84.37%
50-day SMA	$3.36
50-day SMA vs 200-day SMA	50under200
52-week high	$4.83
52-week high date	2026-03-10
52-week low	$2.43
52-week low date	2026-10-14
5Y price change	-97.44%
5Y return CAGR	-51.95%
5Y total return	-97.44%
6M price change	-21.14%
6M total return	-21.14%
All-time high	$717.90
All-time high date	2019-03-22
All-time low	$1.35
All-time low date	2025-08-11
Average true range (ATR)	$0.21
Average volume	655.7K
Beta (1Y)	1.69
Beta (2Y)	1.24
Beta (5Y)	0.46
Change from 52-week high	-31.26%
Change from 52-week low	36.63%
Change from all-time high	-99.54%
Change from all-time low	145.93%
Change from open	4.73%
Day's gap	-2.46%
Dollar volume	$1.4M
High price	$3.35
Low price	$3.17
Monthly RSI	35.65
Open price	$3.17
Position in 52-week range	83.33%
Premarket change	0.92%
Premarket close	$3.25
Premarket price	$3.28
Previous close	$3.25
Price vs 150-day SMA	-13.65%
Price vs 20-day SMA	14.52%
Price vs 200-day SMA	-12.75%
Price vs 50-day SMA	-1.07%
Relative volume	0.67
RSI	59.63
Sharpe ratio	0.14
Sharpe ratio (3Y)	0.01
Sharpe ratio (5Y)	-0.12
Sortino ratio	0.3
Sortino ratio (3Y)	0.07
Sortino ratio (5Y)	-0.14
Volume	435.7K
Weekly RSI	45.58
YTD price change	-17%
YTD total return	-17%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	57.2M
Float percentage	57.71%
Shares change (QoQ)	0.04%
Shares change (YoY)	1,374.07%
Shares held by insiders	0.69%
Shares held by institutions	62.03%
Shares outstanding	99.1M
Short % of float	13.09%
Short % of shares	7.56%
Short ratio	6.4 days

Deeper analysis on XFOR

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this XFOR report

Is a complete XFOR research report available?

No complete published report is available for X4 Pharmaceuticals, Inc. (XFOR) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

X4 Pharmaceuticals, Inc. (XFOR)

Price

Financial snapshot

Fair-value bridge

Latest news · XFOR

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All XFOR indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on XFOR

Frequently asked questions